Puma Biotechnology develops and sells cancer treatments, including the breast cancer drug NERLYNX. It last closed at $7.05 on Nov 20, down 0.98% on the day. The next earnings report for PBYI is expected around Thu, Feb 25, 2027, after the close. For the quarter ended Sep 2026, PBYI reported EPS of $0.11 on revenue of $55.1M, with revenue up 1.1% from a year ago. Over its last 8 reports the stock moved an average of 14.1% the session after earnings. Over the last 12 months PBYI insiders bought $0 of stock on the open market and sold $2.1M, according to SEC Form 4 filings.
AI Auto Pilots
Is PBYI in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold PBYI.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on PBYIStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
PBYI · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend, oversold
The stock is 27% below its 20 day and 35% below its 50 day average. It is 14% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 24), oversold. The nearest support is the swing low (Jun 16) at $6.96, and the nearest resistance the Pivot at $7.06.
Short trendBearish
Long trendBullish
MomentumWeak
StretchOversold
VolatilityHigh, 6.8%/day
Key levels
$11.5052 week high+63.1%
$9.5450 day average+35.3%
$9.08100 day average+28.8%
$8.9420 day average+26.8%
$8.04200 day average+14.0%
$7.45Swing high (May 27)+5.7%
$7.21Pivot R1+2.3%
$7.06Pivot+0.1%
$7.05Last close
$6.96Swing low (Jun 16)−1.3%
$6.90Pivot S1−2.1%
$4.7952 week low−32.1%
Indicators
RSI (14)
24.46
Oversold below 30
Oversold
MACD
-0.81
Below its signal line
Bearish
Stochastic
5.4
Near the bottom of its range
Oversold
ADX (14)
37.9
Trending down
Williams %R
-96.5
Oversold below −80, overbought above −20
Oversold
CCI (20)
-92.2
Oversold below −100, overbought above 100
Neutral
Rate of change
−14.6%
Change over 10 sessions
Bearish
ATR (14)
$0.48
Typical daily range, 6.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Pullback inside a longer uptrend
Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityNormal, 14.5%/day
Key levels
$11.5052 week high+63.1%
$9.5450 day average+35.3%
$9.08100 day average+28.8%
$8.9420 day average+26.8%
$8.04200 day average+14.0%
$7.45Swing high (May 27)+5.7%
$7.21Pivot R1+2.3%
$7.06Pivot+0.1%
$7.05Last close
$6.96Swing low (Jun 16)−1.3%
$6.90Pivot S1−2.1%
$4.7952 week low−32.1%
Indicators
RSI (14)
39.83
Weak, oversold below 30
Neutral
MACD
0.29
Below its signal line
Bearish
Stochastic
9.4
Near the bottom of its range
Oversold
ADX (14)
46.8
Strong downtrend
Williams %R
-97.0
Oversold below −80, overbought above −20
Oversold
CCI (20)
-159.8
Oversold below −100, overbought above 100
Oversold
Rate of change
−22.7%
Change over 10 sessions
Bearish
ATR (14)
$1.02
Typical daily range, 14.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Above
What happened before, for PBYI
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how PBYI did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow PBYI usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for PBYIHow many large options trades hit PBYI, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in PBYI in the last 90 days.
From SEC Form 4 filings by PBYI's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PBYI is in one of them and how their past PBYI trades turned out.
From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data
About Puma Biotechnology
Puma Biotechnology is a biopharmaceutical company based in Los Angeles, California, that develops and sells cancer treatments. Its main commercial product is NERLYNX, an oral form of neratinib approved in the United States for certain types of HER2 positive breast cancer. In the United States the company markets NERLYNX through its own sales force, and it works with partners in other countries to sell the drug there. It is also developing alisertib, an investigational cancer drug aimed at small cell lung cancer and hormone receptor positive breast cancer.